Teva Announces priority review granted by FDA for SD-809 for treatment of TD
Teva announced the FDA has accepted the New Drug Application nd granted Priority Review for SD-809 (deutetrabenazine) for treatment of tardive dyskinesia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 30, 2017. February 28, 2017